Interestingly, a recent study indicated that in ERα-positive breast cancers treated with TAM the ratio of nuclear AR to ER (AR:ER) rather than the level of AR expression may play a role in disease progression and response to treatment. This evidence concerns the gene AR and breast carcinoma.